Cardiotoxicity of BRAF/MEK Inhibitors: A Longitudinal Study Incorporating Contemporary Definitions and Risk Scores
Authors' conclusion
BRAF and MEK inhibitor-associated CTRCD is common.
Study context
- Population
- Patients with melanoma treated with BRAF and MEK inhibitors, June 2017–June 2020
- Participants
- 63 patients
- Outcome
- Incidence of cancer therapy-related cardiac dysfunction (CTRCD; mild, moderate or severe by ICOS definitions)
Methodological detailscancer hospital network
- Cancer hospital network
Main finding
As reported in the abstract
CTRCD
Any cancer therapy-related cardiac dysfunction (CTRCD)
27%
Mild CTRCD
17%
Moderate CTRCD
10%
Severe CTRCD or symptomatic HF
0
Observational data: associations, not effects.
Further findings
LV internal diameter in diastole, moderate CTRCD vs none
P = 0.023
LV internal diameter in systole, moderate CTRCD vs none
P = 0.039
CTRCD by HFA/International Cardio-Oncology Society (ICOS) baseline risk
- CTRCD in patients at "low" and "medium" baseline risk
- 82%
Baseline LVEF and global longitudinal strain, moderate CTRCD vs none
- Not different in patients who developed moderate CTRCD vs those who did not
Original publication
Cardiotoxicity of BRAF/MEK Inhibitors: A Longitudinal Study Incorporating Contemporary Definitions and Risk Scores. JACC CardioOncol. Published 6 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →